Immage Biotherapeutics Corp.
Immage Biotherapeutics Corp.
Your view on IMMG
Overview
What the company does, where it operates, and who runs it.
About Immage Biotherapeutics Corp.
- Industry
- Financial - Conglomerates
- Sector
- Financial Services
- CEO
- Zhi Cong Mou
- Headquarters
- 10411 Motor City Drive, Bethesda, US
- Industry
- Financial - Conglomerates
- Sector
- Financial Services
- CEO
- Zhi Cong Mou
- Headquarters
- 10411 Motor City Drive, Bethesda, US
Immage Biotherapeutics Corp. does not have significant business operations. Previously, it was engaged in developing novel immunotherapy biologics to treat various cancers in the United States. The company was formerly known as Epicure Charcoal, Inc. and changed its name to Immage Biotherapeutics Corp. in June 2015.
The company was founded in 2012 and is headquartered in Bethesda, Maryland. Immage Biotherapeutics Corp. is a subsidiary of Coventry International Limited.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Immage Biotherapeutics Corp., and the rating behind it. IMMG last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Immage Biotherapeutics Corp.. Starting points for Immage Biotherapeutics Corp.: beta 32.51 — an Financial - Conglomerates name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Immage Biotherapeutics Corp.. Immage Biotherapeutics Corp. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Immage Biotherapeutics Corp.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Immage Biotherapeutics Corp.. Immage Biotherapeutics Corp. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Immage Biotherapeutics Corp. valued side by side against its closest peers. Immage Biotherapeutics Corp. is measured against Financial - Conglomerates peers within the Financial Services sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Immage Biotherapeutics Corp., and how their positions are changing. At a $15,174 market value, institutional positions materially move Immage Biotherapeutics Corp.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Immage Biotherapeutics Corp. executives and directors. Shares of Immage Biotherapeutics Corp. have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Immage Biotherapeutics Corp.. Immage Biotherapeutics Corp. is a $15,174 Financial Services company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Immage Biotherapeutics Corp.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Immage Biotherapeutics Corp.. Coverage tracks Immage Biotherapeutics Corp. within Financial - Conglomerates (Financial Services). Press releases and market coverage, newest first.